Stratos Wealth Advisors’s AbCellera Biologics ABCL Stock Holding History

Stratos Wealth Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$177K	Sell	22,500 -500	-2%	-$2.44K	0.01%	621
2026 Q1	$80.3K	Hold	23,000	–	–	﹤0.01%	602
2025 Q4	$78.7K	Buy	23,000 +4,000	+21%	+$17.9K	﹤0.01%	647
2025 Q3	$95.6K	Buy	+19,000	New	+$83.7K	﹤0.01%	667
2025 Q2	–	Sell	-12,000	Closed	-$26.8K	–	670
2025 Q1	$26.8K	Buy	+12,000	New	+$34.4K	﹤0.01%	660
2024 Q4	–	Sell	-45,500	Closed	-$118K	–	712
2024 Q3	$118K	Hold	45,500	–	–	0.01%	716
2024 Q2	$135K	Hold	45,500	–	–	0.01%	680
2024 Q1	$206K	Buy	45,500 +2,000	+5%	+$10.2K	0.01%	626
2023 Q4	$248K	Sell	43,500 -5,000	-10%	-$23.2K	0.01%	593
2023 Q3	$223K	Buy	+48,500	New	+$295K	0.01%	598

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Stratos Wealth Advisors's ABCL Position: Q2 2026 in Review

Stratos Wealth Advisors reduced its AbCellera Biologics (ABCL) stake by 2.2% in Q2 2026, selling an estimated $2.44K and leaving 22,500 shares worth $177K. The position accounts for 0.01% of the portfolio, ranked #621.

Stratos Wealth Advisors first reported a position in ABCL in Q3 2023 and has held it in 10 quarters since. The position peaked at $248K in Q4 2023. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Stratos Wealth Advisors held 22,500 shares of AbCellera Biologics worth $177K as of Q2 2026.
Stratos Wealth Advisors sold 500 AbCellera Biologics shares in Q2 2026, an estimated $2.44K.
AbCellera Biologics made up 0.01% of Stratos Wealth Advisors's portfolio in Q2 2026, its #621 holding.
Stratos Wealth Advisors first reported a position in AbCellera Biologics in Q3 2023 and has held it in 10 quarters since.
Stratos Wealth Advisors's AbCellera Biologics position peaked at $248K in Q4 2023.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Stratos Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.